公开(公告)号：US20170165262A1

公开(公告)日：2017-06-15

申请号：US15436037

申请日：2017-02-17

Applicant: FUJIFILM Corporation

Inventor： Tomoki NAOE ,  Hitoshi KIYOI ,  Shinji HAGIWARA ,  Masaru TAKASAKI ,  Daisuke HIRANO ,  Toshiyuki NAKATANI ,  Takeshi YAMAURA

IPC: A61K31/506 ,  A61K31/505 ,  A61K31/5377

CPC classification number: A61K31/506 ,  A61K31/505 ,  A61K31/5377 ,  C12N9/12 ,  C12N9/1205 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation.

公开(公告)号：US20210386768A1

公开(公告)日：2021-12-16

申请号：US17459412

申请日：2021-08-27

Applicant: FUJIFILM Corporation

Inventor： Hidetoshi MURAO ,  Hayato OGURA ,  Koichi SAITO ,  Shinji HAGIWARA ,  Takeshi YAMAURA ,  Toshiyuki NAKATANI ,  Hitoshi KIYOI ,  Yuichi ISHIKAWA

IPC: A61K31/706 ,  A61K31/505 ,  A61K31/635

Abstract: An object of the present invention is to provide a combination medicine that exhibits a practical curing effect on a tumor such as acute myeloid leukemia. According to the present invention, there is provided a combination medicine, which contains a compound represented by General Formula [1] specified in the present specification, such as (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide or a salt thereof, and at least one selected from the group consisting of a BCL-2 inhibitor and a pyrimidine antimetabolite.